AVImark vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Widely deployed on-premise veterinary PMS now owned by Covetrus and integrated with IDEXX reference labs. Large installed base of independent US small-animal practices that adopted AVImark as the de facto standard before cloud alternatives;
About
AVImark is a veterinary practice management software system that has been widely deployed in independent veterinary practices across the United States for decades, and is currently owned by Covetrus—the animal health technology and distribution company formed from the combination of Henry Schein Animal Health and Vets First Choice, which was subsequently acquired by IDEXX Laboratories. AVImark's strength lies in its deep penetration of the independent small-animal practice market, where it became the de facto standard system for many practices that adopted practice management software in the 1990s and 2000s. The software provides scheduling, medical records, invoicing, inventory management, and client communication in an on-premise Windows-based system that has been continuously developed and supported through multiple ownership transitions.\n\nAVImark's integration with IDEXX's reference laboratory and diagnostic services is a significant feature of the current product, allowing practices to send laboratory orders electronically and receive results directly within the AVImark patient record. This IDEXX connectivity is particularly valuable for practices that are already IDEXX lab customers and want to reduce manual result transcription. Covetrus has also integrated AVImark with its online pharmacy and prescription management services, creating a connected ecosystem that links practice management, diagnostics, and medication dispensing for AVImark-using clinics.\n\nAVImark faces competitive pressure from cloud-native veterinary practice management systems including Shepherd, ezyVet, and Digitail that offer more modern user experiences, mobile accessibility, and frequent feature updates without requiring on-premise hardware. Covetrus has been investing in a cloud migration path for AVImark customers while also offering its newer Pulse platform as a cloud-native alternative for practices ready to move off legacy on-premise systems. The installed base of AVImark users represents a significant asset for Covetrus but also a long-term migration and retention challenge as the industry shifts toward cloud deployment.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.